An update on the relevance of vaccine research for the treatment of metastatic melanoma.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2017-12-01 Epub Date: 2017-11-23 DOI:10.2217/mmt-2017-0021

Robert O Dillman

引用次数: 11

Abstract

Signal transduction inhibitors and anticheckpoint antibodies have significantly improved survival for metastatic melanoma patients, but most still die within 5 years. Vaccine approaches to induce immunity to well-characterized melanoma-associated antigens, or to antigens expressed on allogeneic tumor cell lines, have not resulted in approved agents. Despite the limitations associated with the immunosuppressive tumor microenvironment, there now is one intralesional autologous vaccine approved for patients who have primarily soft-tissue metastases. There is continued interest in patient-specific vaccines, especially dendritic cell vaccines that utilize ex vivo loading of autologous antigen, thus bypassing certain in vivo immunosuppressive cells and cytokines. Because of their mechanism of action and limited toxicity, they are potentially synergistic or additive to other antimelanoma therapies.

查看原文本刊更多论文

疫苗研究与转移性黑色素瘤治疗相关性的最新进展。

信号转导抑制剂和抗检查点抗体显著提高了转移性黑色素瘤患者的生存率，但大多数患者仍在5年内死亡。诱导对特征良好的黑色素瘤相关抗原或对异基因肿瘤细胞系上表达的抗原免疫的疫苗方法尚未产生批准的制剂。尽管存在与免疫抑制肿瘤微环境相关的局限性，但现在有一种病变内自体疫苗被批准用于主要有软组织转移的患者。人们继续对患者特异性疫苗感兴趣，特别是利用自体抗原的离体装载，从而绕过某些体内免疫抑制细胞和细胞因子的树突状细胞疫苗。由于它们的作用机制和有限的毒性，它们有可能与其他抗黑色素瘤疗法协同或相加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.